Two-drug combo curbs drinking for people battling severe alcoholism
A combo of an allergy drug and a blood pressure med appears to lower daily drinking in folks battling severe alcoholism, French researchers report.
Apr 18, 2024
0
42
A combo of an allergy drug and a blood pressure med appears to lower daily drinking in folks battling severe alcoholism, French researchers report.
Apr 18, 2024
0
42
The U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory multiple myeloma.
Apr 10, 2024
0
1
AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor, demonstrated a manageable safety profile in both recurrent and newly diagnosed glioblastoma (GBM) patients when given in combination with standard-of-care radiotherapy ...
Apr 9, 2024
0
1
A new study, led by Prof. Liu from the department of pharmacy, University of Electronic Science and Technology of China, discovered that the extracellular cell matrix (ECM) could induce the drug resistance of breast cancer ...
Apr 8, 2024
0
7
A pilot study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that for people with borderline resectable pancreatic cancer, administrating an immunotherapy drug in combination with chemotherapy ...
Apr 5, 2024
0
2
The U.S. Food and Drug Administration (FDA) has cleared the first prescription digital therapeutic authorized for the adjunctive treatment of major depressive disorder (MDD) symptoms.
Apr 5, 2024
0
2
The U.S. Food and Drug Administration has approved Winrevair (sotatercept-csrk) as an injectable treatment for pulmonary arterial hypertension (PAH) in adults.
Mar 29, 2024
0
1
An estimated 2.2 million people suffer from lung cancer worldwide, making it the second most common type of cancer. Though improvements in treatment have been made, the overall survival rate of lung cancer patients is low, ...
Mar 27, 2024
0
3
Gastric cancer ranks among the most widespread diseases in Asian populations, with South Koreans experiencing the third-highest incidence globally in 2020, as reported by the International Agency for Research on Cancer.
Mar 21, 2024
0
0
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel [liso-cel]) as the first CD19-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed ...
Mar 19, 2024
0
3